The extracellular matrix (ECM) is one of the major components of tumors that plays multiple
crucial roles, including mechanical support, modulation of the microenvironment, and a …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …

Approximately 10% of EGFR-activating mutations occur as in-frame insertion mutations in
exon 20 of the EGFR kinase domain (EGFR ins20). EGFR ins20 mutations have not …

Objective To compare the efficacy and safety of first line treatments for patients with
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review
on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - PMC …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current
recommended option for the first-line treatment of patients with EGFR-mutant non-small cell …

Purpose: Dynamic changes in circulating tumor DNA (ctDNA) are under investigation as an
early indicator of treatment outcome. Experimental Design: Serial plasma ctDNA (baseline, 8 …

Introduction Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the
first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients …